Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Brief Summary: This is a randomized, open-label, multicenter, Phase 3 study comparing the efficacy and safety of eribulin with dacarbazine in subjects with advanced soft tissue sarcoma who have disease progression within 6 months prior to study enrolment following standard therapies which must have included an anthracycline, unless contraindicated and then at least one additional regimen after failure of the anthracycline.


Options:
A: Arm Label: gemcitabine/docetaxel then doxorubicin; Type: OTHER; Interventions: Drug: gemcitabine, docetaxel, doxorubicin | Intervention Type: DRUG; Name: gemcitabine, docetaxel, doxorubicin; Assigned to Arm(s): gemcitabine/docetaxel then doxorubicin
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Eribulin mesylate 1.4 mg/m^2 intravenous | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV | Intervention Type: DRUG; Name: Eribulin mesylate 1.4 mg/m^2 intravenous; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV; Assigned to Arm(s): Arm B
C: Arm Label: No radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery | Arm Label: Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Drug: Pemetrexed, Procedure: Therapeutic conventional surgery, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: PROCEDURE; Name: Therapeutic conventional surgery; Assigned to Arm(s): No radiotherapy, Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy
D: Arm Label: Part A, Group 1; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part A, Group 2; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 1; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 2; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Methotrexate | Arm Label: Part B, Group 3; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 4; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 50 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 5; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 25 mg, Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: CNTO 136 100 mg; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 2, Part B, Group 3 | Intervention Type: DRUG; Name: CNTO 136 50 mg; Assigned to Arm(s): Part B, Group 4 | Intervention Type: DRUG; Name: CNTO 136 25 mg; Assigned to Arm(s): Part B, Group 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 3, Part B, Group 4, Part B, Group 5 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 2, Part B, Group 3, Part B, Group 4, Part B, Group 5

Answer: B